Battelle Ventures Spins Out Hepregen with $5M in Funding to Develop 'Microliver' Tox Platform

The Medford, Mass.-based company will use the cash to continue developing its 2D microliver platform, which is designed to screen compounds for ADME/tox assessment and be used in drug discovery.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.